The FDA recently approved a new non-opioid analgesic, providing a significant advancement in acute pain management. According to FDA officials, this therapeutic class can reduce the complications associated with opioid use, presenting an important alternative for the millions experiencing moderate-to-severe acute pain each year. Vertex, the drug's developer, stated the medication will cost $31 daily, which, while higher than generics, may be ultimately cost-saving by preventing opioid addiction. This approval may transform the standards of care in pain management significantly for patients.
The approval "is an important public health milestone in acute pain management," said Jacqueline Corrigan-Curay, J.D., M.D., highlighting the significance of the new treatment.
Reshma Kewalramani, CEO of Vertex, referred to the approval as a "historic milestone for the 80 million people in America" needing moderate-to-severe acute pain management.
Collection
[
|
...
]